Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
- Chemical substance: Diclofenac sodium
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Flamrase 50 EC tablets
1001010C0BKABAE
|
Flamrase | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Flamrase 75mg SR tablets
1001010C0BKADAL
|
Flamrase | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Flamrase SR 100mg tablets
1001010C0BKACAF
|
Flamrase | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Flexotard MR 100mg tablets
1001010C0BXAAAF
|
Flexotard | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Lofensaid 25mg gastro-resistant tablets
1001010C0BRABAD
|
Lofensaid | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Lofensaid 50mg gastro-resistant tablets
1001010C0BRAAAE
|
Lofensaid | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Lofensaid Retard 100 tablets
1001010C0BRADAF
|
Lofensaid | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Lofensaid Retard 75 tablets
1001010C0BRACAL
|
Lofensaid | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Masidemen 50mg/200microgram gastro-resistant tablets
1001010C0CPAAAM
|
Masidemen | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Masidemen 75mg/200microgram gastro-resistant tablets
1001010C0CPABAX
|
Masidemen | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Misofen 50mg/200microgram gastro-resistant tablets
1001010C0CNAAAM
|
Misofen | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Misofen 75mg/200microgram gastro-resistant tablets
1001010C0CNABAX
|
Misofen | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Mobigel 4% spray
1003020U0BHAAAH
|
Mobigel | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Mobigel Paineze 4% spray
1003020U0BHACAH
|
Mobigel | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Pennsaid 16mg/ml cutaneous solution
1003020U0BEAAAD
|
Pennsaid | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Rheumatac Retard 75 tablets
1001010C0CEAAAL
|
Rheumatac | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Rhumalgan CR 100 tablets
1001010C0BDADAF
|
Rhumalgan | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Rhumalgan CR 75 tablets
1001010C0BDACAL
|
Rhumalgan | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Rhumalgan SR 75mg capsules (Actavis)
1001010C0BDAIAW
|
Rhumalgan | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Rhumalgan SR 75mg capsules (Almus)
1001010C0BDAGAW
|
Rhumalgan | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Rhumalgan SR 75mg capsules (Sandoz Ltd)
1001010C0BDAFAW
|
Rhumalgan | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Rhumalgan XL 100mg capsules (Actavis)
1001010C0BDAJAN
|
Rhumalgan | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Rhumalgan XL 100mg capsules (Almus)
1001010C0BDAHAN
|
Rhumalgan | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Rhumalgan XL 100mg capsules (Sandoz)
1001010C0BDAEAN
|
Rhumalgan | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Slofenac 75mg SR tablets
1001010C0BWAAAL
|
Slofenac | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.